Kapil Dikshit, Bari Aafreen, Sharma Namrata, Velpandian Thirumurthy, Sinha Rajesh, Maharana Prafulla, Kaur Manpreet, Agarwal Tushar
Cornea, Cataract and Refractive Surgery, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, Delhi, India.
Ocular Pharmacology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, Delhi, India.
Indian J Ophthalmol. 2025 Jun 1;73(Suppl 3):S428-S434. doi: 10.4103/IJO.IJO_1572_24. Epub 2025 Apr 17.
To assess the role of oral bio-enhanced curcumin in dry eye disease (DED).
Randomized, double-masked, placebo-controlled clinical study conducted at a tertiary eye center.
Forty patients of bilateral mild to moderate DED were randomized in two groups - group A (topical carboxy methyl cellulose QID + oral placebo) and group B (topical carboxy methyl cellulose QID + oral bio-enhanced curcumin). The objective parameters of DED were quantified at baseline and compared at 3 months follow-up.
At three months follow-up, there was significant improvement in curcumin group in terms of Ocular Surface Disease Index (OSDI) score ( P = 0.002), tear meniscus height (TMH) ( P = 0.002), tear volume ( P = 0.006), tear break-up time (TBUT) ( P < 0.001), non-invasive break-up time (NIBUT) ( P = 0.026), lipid layer thickness (LLT) ( P = 0.01), and decrease in bulbar redness ( P = 0.002). There was no significant improvement in limbal redness ( P = 0.097), corneal-staining score ( P = 0.93), and Schirmer's test ( P = 0.42). Mild adverse drug reaction was observed in three cases of the curcumin group and one case of group A.
Oral bio-enhanced curcumin is a safe and effective treatment modality in cases of mild to moderate DED. It effectively improves the tear film stability, LLT, and TMH and reduces the bulbar redness.
评估口服生物增强型姜黄素在干眼症（DED）中的作用。
在一家三级眼科中心进行的随机、双盲、安慰剂对照临床研究。
40例双侧轻至中度DED患者被随机分为两组——A组（局部用羧甲基纤维素，每日4次+口服安慰剂）和B组（局部用羧甲基纤维素，每日4次+口服生物增强型姜黄素）。在基线时对DED的客观参数进行量化，并在3个月随访时进行比较。
在3个月随访时，姜黄素组在眼表疾病指数（OSDI）评分（P = 0.002）、泪河高度（TMH）（P = 0.002）、泪液量（P = 0.006）、泪膜破裂时间（TBUT）（P < 0.001）、非侵入性泪膜破裂时间（NIBUT）（P = 0.026）、脂质层厚度（LLT）（P = 0.01）以及球结膜充血减轻（P = 0.002）方面有显著改善。角膜缘充血（P = 0.097）、角膜染色评分（P = 0.93）和泪液分泌试验（P = 0.42）无显著改善。姜黄素组有3例和A组有1例出现轻度药物不良反应。
口服生物增强型姜黄素是治疗轻至中度DED的一种安全有效的治疗方式。它能有效改善泪膜稳定性、LLT和TMH，并减轻球结膜充血。
